We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) on Tuesday said the U.S. Federal Trade Commission has requested more information as part of its antitrust review of the company's planned $74 billion acquisition of Celgene Corp. (CELG).
The New York biopharmaceutical company said the so-called "second request" from the FTC involves a review of marketed and pipeline products for the treatment of psoriasis.
Bristol-Myers said the companies plan to work with the FTC to show that the deal won't harm competition.
Bristol-Myers said the FTC's request extends the antitrust waiting period for the deal, but said it still expects to complete the Celgene acquisition in the third quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 26, 2019 07:42 ET (11:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
